Stumbled onto this 2019 article and was reminded of earlier theories... fwiw, rbbm
VANCOUVER _ A disinterested pharmaceutical industry and the conundrum of finding a convincing placebo are just two reasons experts say
weeklyvoice.com
''VANCOUVER _ A disinterested pharmaceutical industry and the conundrum of finding a convincing placebo are just two reasons experts say there has been little quality research into medicinal marijuana.''
''Marijuana’s unconventional journey onto the medical market puts it at odds with more mainstream medications, which typically undergo years of costly scrutiny before being approved for use, said Mark Ware, a pain researcher at McGill University Health Centre in Montreal.''
“We’re in a unique place because a lot of l
arge pharmaceutical companies are reluctant to fund these studies where they don’t necessarily see the incentive for something that they aren’t able to patent,” said Laprairie, who conducts cannabinoid research at the university.''
A year before his murder, the Apotex founder had agreed to work with CannTrust to produce a slow-release medical marijuana pill that would treat chronic pain, depression, PTSD and more. Sherman and others felt the “pot pill” could be a game-changer in the industry and a disrupter to Big Pharma.
www.thestar.com
2019
''A year before his murder, the Apotex founder had agreed to work with CannTrust to produce a slow-release medical marijuana pill that would treat chronic pain, depression, PTSD and more.
Sherman and others felt the “pot pill” could be a game-changer in the industry and a disrupter to Big Pharma.''
''The project to develop a slow-release medical marijuana pill was on.
Just a year before his murder, Sherman gave the green light on what scientists at his generic drug firm, Apotex, and marijuana firm CannTrust call the “pharmaceuticalization of marijuana.” People suffering from chronic pain, depression, anxiety, seizures, post-traumatic stress disorder and other afflictions might one day benefit, say investors in the project.
“I think Barry decided Apotex better get in on the ground level,” said Aubrey Dan, a businessman who is involved in the project, but was once a Sherman rival in the generic drug world. “Barry was a true entrepreneur. He has always been a risk taker.”
''Health Canada approval is estimated to be two years away, but if it comes, t
he pills would be a disrupter in the Big Pharma brand-name drug world, and for Sherman’s own generic firm, providing an alternative to highly addictive opioids and other pharmaceuticals. People who worked with the late Sherman say the so-called “pot pill” will be one of his greatest legacies.''
'
'Pharmaceutical companies, both brand name and generic, produce many drugs (including fentanyl and other highly addictive opioids) that might be replaced by a cannabis pill, according to proponents of the CannTrust plan. That’s why they believe their product might “disrupt” the market.''
'
'After considering the idea for a time, Sherman said simply, “Let’s do it.” That led to the creation of an agreement between Apotex and CannTrust on Dec. 23, 2016, to “develop novel dosage formats and products,” according to the long-form prospectus Canntrust filed in advance of the company going public.''
''Despite Sherman’s death, both CannTrust and Apotex plan to continue the project, with scientists at Apotex working on unique dosage formats.
Sherman’s death was noted in a CannTrust press release on Dec. 18, 2017, three days after the bodies of the couple were discovered.''
